<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03145207</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00067033</org_study_id>
    <nct_id>NCT03145207</nct_id>
  </id_info>
  <brief_title>PK and DPK of Lidocaine Dermal Products</brief_title>
  <official_title>Evaluation of Bioavailability of Lidocaine Dermal Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a bioequivalence study to compare lidocaine release between a brand name and generic
      skin patches in healthy adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is intended to determine the effect of heat on lidocaine patches. This
      study will use lidocaine patches (brand name and generic patches) that have been approved by
      the Food and Drug Administration (FDA) and are already sold to customers in the United
      States, and will not include any placebos.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2016</start_date>
  <completion_date type="Actual">May 15, 2020</completion_date>
  <primary_completion_date type="Actual">January 10, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Maximum Serum Concentration (Cmax)</measure>
    <time_frame>six study sessions for each participant; through 15 h each study session</time_frame>
    <description>maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Heat Effect</condition>
  <arm_group>
    <arm_group_label>name brand patch</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>name brand lidocaine patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic patch</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>generic lidocaine patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>name brand patch-early</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>name brand lidocaine patch-early</description>
  </arm_group>
  <arm_group>
    <arm_group_label>name brand patch-late</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>name brand lidocaine patch-late</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic patch-early</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>generic lidocaine patch-early</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic patch-late</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>generic lidocaine patch-late</description>
  </arm_group>
  <arm_group>
    <arm_group_label>both patches</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>brand name and generic lidocaine patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine patch</intervention_name>
    <description>lidocaine patch</description>
    <arm_group_label>both patches</arm_group_label>
    <arm_group_label>generic patch</arm_group_label>
    <arm_group_label>generic patch-early</arm_group_label>
    <arm_group_label>generic patch-late</arm_group_label>
    <arm_group_label>name brand patch</arm_group_label>
    <arm_group_label>name brand patch-early</arm_group_label>
    <arm_group_label>name brand patch-late</arm_group_label>
    <other_name>skin patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or non-pregnant, women who are of any ethnic background between the age of 18 and
             45 years old.

          2. Subjects must be non-smokers (must have refrained from the use of nicotine-containing
             substances, including tobacco products (e.g., cigarettes, cigars, chewing tobacco,
             snuff, gum, patches or electronic cigarettes) over the previous 2 months and are not
             currently using tobacco products.

          3. Provide written informed consent before initiation of any of the study procedures.

          4. Agrees not to participate in another clinical trial/study or to participate in an
             investigational drug study for at least 1 month after the last study session.

          5. Able to adhere to the study restrictions and protocol schedule.

          6. Able to participate in all study sessions.

          7. Has a volar forearm of either at least 24 cm (9.45 inches) in length or of sufficient
             size that can accommodate the formulations to be tested in a study area that begins at
             least 5 cm (1.97 inches) above the wrist and ends a minimum of 0.5 cm (0.197 inches)
             below the antecubital fossa (i.e., the bend in the arm at the elbow).

          8. Subjects have upper arms (minimum 28 cm (11 inch) circumference) large enough to allow
             for the placement of two 140 cm2 patches on one upper arm or one 140 cm2 patch on each
             upper arm.

          9. Subjects deemed to be healthy as judged by the MAI and determined by medical history,
             physical examination and medication history.

         10. Negative urine drug screening test.

         11. Have normal screening laboratories for WBC, CBC, Hgb, platelets, sodium, potassium,
             chloride, bicarbonate, BUN, creatinine, ALT and AST.

         12. Have normal screening laboratories for urine protein and urine glucose.

         13. Female subjects must be of non-childbearing potential (as defined as surgically
             sterile [i.e., history of hysterectomy or tubal ligation] or postmenopausal for more
             than 1 year), or if of childbearing potential must be non-pregnant at the time of
             enrollment and on the morning of each procedure day, and must agree to use hormonal or
             barrier birth control such as implants, injectables, combined oral contraceptives,
             some intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner.

         14. Agrees not to donate blood to a blood bank throughout participation in the study and
             at least 3 months after the last procedure day.

         15. Have a normal ECG; must not have the following to be acceptable: pathologic Q wave
             abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right
             bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats
             per minute).

         16. Have normal vital signs:

               -  Temperature 35-37.9°C (95-100.3°F)

               -  Systolic blood pressure 90-140 mmHg

               -  Diastolic blood pressure 60-90 mmHg

               -  Heart rate 55-100 beats per minute

               -  Respiration rate 12-20 breaths per minute

        Exclusion Criteria:

          1. Women who are pregnant, lactating, breast feeding or have a positive serum pregnancy
             test at enrollment or positive urine pregnancy test on the morning of each study
             session.

          2. Smokers (current use or use over the previous 2 months of nicotine-containing
             substances, including tobacco products (e.g., cigarettes, cigars, chewing tobacco,
             snuff, gum, patches or electronic cigarettes).

          3. Participation in any ongoing investigational drug trial/study or clinical drug
             trial/study.

          4. History of chronic obstructive pulmonary disease or cor pulmonale, or substantially
             decreased respiratory reserve, hypoxia, hypercapnia or pre-existing respiratory
             depression.

          5. Active positive Hepatitis B, C and/or HIV serologies (see Appendix B).

          6. Known anemia.

          7. Positive urine drug screening test.

          8. Use of chronic prescription medication during the period 0 to 30 days; or over-the
             counter medication (e.g. antihistamines or topical corticosteroids) and short term
             (&lt;30 days) prescription medications during the period 0 to 3 days before a study
             session (vitamin, herbal supplements and birth control medications not included).

          9. Donation or loss of greater than one pint of blood within 60 days of entry to the
             study.

         10. Any prior adverse reaction to lidocaine. Hypersensitivity to lidocaine, known history
             of hypersensitivity to local anesthetics of the amide type, other excipients in the
             patches tested or to adhesives on tapes used to cover or tape strip treatment sites.

         11. Received an experimental agent (vaccine, drug, biologic, device, blood product or
             medication) within 1 month before enrollment in this study or expects to receive an
             experimental agent during the study.

         12. Any condition that would, in the opinion of the Medically Accountable Investigator
             (MAI), place the subject at an unacceptable risk of injury or render the subject
             unable to meet the requirements of the protocol.

         13. Consumption of alcohol within 24 h prior to dose administration.

         14. History as either reported by the subject or evident to the investigator of infectious
             disease or skin infection or of chronic skin disease (e.g., diabetes, psoriasis,
             atopic dermatitis).

         15. Hereditary skin disorders or any skin inflammatory conditions as reported by the
             research participant or evident to the MAI.

         16. History of significant dermatologic cancers (e.g., melanoma, squamous cell carcinoma)
             except basal cell carcinomas that were superficial and did not involve the
             investigative sites.

         17. Subject has an obvious difference in skin color between arms or the presence of a skin
             condition, excessive hair at application site (volar forearms/upper arms), sunburn,
             raised moles and scars, open sores at application site (volar forearms/upper arms),
             scar tissue, tattoo or coloration that would interfere with placement of formulations,
             skin assessment or reactions to lidocaine.

         18. BMI ≥30 kg/m2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Audra Stinchcomb, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Baltimore School of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hazem Hassan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Baltimore School of Pharmacy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Clinical Research Center (GCRC) at the University of</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <results_first_submitted>May 15, 2020</results_first_submitted>
  <results_first_submitted_qc>June 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 22, 2020</results_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Audra Stinchcomb</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT03145207/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lidocaine</title>
          <description>Session 1-name brand patch Session 2-generic lidocaine patch Session 3-name brand patch with early heat application Session 4-name brand patch with late heat application Session 5-generic patch with early heat application Session 6-generic patch with late heat application Session 7-name brand and generic lidocaine patch pieces with skin tape stripping
The same 12 volunteers completed each of the seven study sessions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14">The same 12 volunteers completed each of the seven study sessions.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>volunteer started taking allergy shots</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>baseline blood pressure high</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lidocaine</title>
          <description>Session 1-name brand patch Session 2-generic lidocaine patch Session 3-name brand patch with early heat application Session 4-name brand patch with late heat application Session 5-generic patch with early heat application Session 6-generic patch with late heat application Session 7-name brand and generic lidocaine patch pieces with skin tape stripping</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.14" spread="7.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Maximum Serum Concentration (Cmax)</title>
        <description>maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered</description>
        <time_frame>six study sessions for each participant; through 15 h each study session</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Name Brand Patch</title>
            <description>Session 1-name brand patch</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Generic Patch</title>
            <description>Session 2-generic lidocaine patch</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine Name Brand Patch Early Heat</title>
            <description>Session 3-name brand patch with early heat application</description>
          </group>
          <group group_id="O4">
            <title>Lidocaine Name Brand Patch Late Heat</title>
            <description>Session 4-name brand patch with late heat application</description>
          </group>
          <group group_id="O5">
            <title>Lidocaine Generic Early Heat</title>
            <description>Session 5-generic patch with early heat application Session 6-generic patch with late heat application Session 7-name brand and generic lidocaine patch pieces with skin tape stripping</description>
          </group>
          <group group_id="O6">
            <title>Lidocaine Generic Late Heat</title>
            <description>Session 6-generic patch with late heat application</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Maximum Serum Concentration (Cmax)</title>
          <description>maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306.8" spread="756.3"/>
                    <measurement group_id="O2" value="214.9" spread="280.5"/>
                    <measurement group_id="O3" value="390.76" spread="387.29"/>
                    <measurement group_id="O4" value="286.49" spread="288.59"/>
                    <measurement group_id="O5" value="368.09" spread="348.93"/>
                    <measurement group_id="O6" value="314.95" spread="287.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>TL-001 (58 days), TL-003 (113 days), TL-005 (135 days), TL-007 (62 days), TL-010 (72 days), TL-017 (388 days), TL-020 (272 days), TL-022 (693 days), TL-023 (61 days), TL-025 (358 days), TL-030 (97 days), TL-031 (108 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Name Brand Patch</title>
          <description>name brand lidocaine patch
Lidocaine patch: lidocaine patch</description>
        </group>
        <group group_id="E2">
          <title>Generic Patch</title>
          <description>generic lidocaine patch
Lidocaine patch: lidocaine patch</description>
        </group>
        <group group_id="E3">
          <title>Name Brand Patch-early</title>
          <description>name brand lidocaine patch-early
Lidocaine patch: lidocaine patch</description>
        </group>
        <group group_id="E4">
          <title>Name Brand Patch-late</title>
          <description>name brand lidocaine patch-late
Lidocaine patch: lidocaine patch</description>
        </group>
        <group group_id="E5">
          <title>Generic Patch-early</title>
          <description>generic lidocaine patch-early
Lidocaine patch: lidocaine patch</description>
        </group>
        <group group_id="E6">
          <title>Generic Patch-late</title>
          <description>generic lidocaine patch-late
Lidocaine patch: lidocaine patch</description>
        </group>
        <group group_id="E7">
          <title>Both Patches</title>
          <description>brand name and generic lidocaine patch
Lidocaine patch: lidocaine patch</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>decreased heart rate</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>increased respiratory rate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>decreased blood pressure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>increased blood pressure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>skin itching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Audra Stinchcomb</name_or_title>
      <organization>University of Maryland, Baltimore School of Pharmacy</organization>
      <phone>410-706-2646</phone>
      <email>astinchc@rx.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

